

PRECEPTORSHIP PROGRAMME

Ovarian Cancer

Multidisciplinary management,
standards of care and future
perspectives

PRAGUE
CZECH REPUBLIC

21-22 APRIL 2017

Chair Jonathan Ledermann, UK

ESMO PRECEPTORSHIP PROGRAMME

OVARIAN CANCER

Multidisciplinary management, standards of care
and future perspectives

Prague, Czech Republic
21-22 April 2017

CHAIR: Jonathan Ledermann, United Kingdom

SPEAKERS: Susana Banerjee, United Kingdom
Nicoletta Colombo, Italy
Christina Fotopoulou, United Kingdom
Christian Marth, Austria
Glenn McCluggage, United Kingdom
Iain McNeish, United Kingdom
Mansoor Mirza, Denmark
Andrés M. Poveda, Spain
Isabelle Ray-Coquard, France
Cristiana Sessa, Switzerland

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment-decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side-effects of treatment

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 21 April 2017

09:00-9:15 15'	Welcome and introduction	Jonathan Ledermann, UK
09:15-10:45 90'	SESSION 1	Chair: Andrés M. Poveda, ES
30'	Pathology and biology of early epithelial ovarian cancer and rare ovarian tumours	Glenn McCluggage, UK
20'	Surgery for early ovarian cancer - Staging and conservative surgery	Christian Marth, AT
20'	Clinical management of early ovarian cancer	Isabelle Ray-Coquard, FR
20'	BRCA mutations in ovarian cancer	Susana Banerjee, UK
10:45-11:15	Coffee Break	
11:15-12:45 90'	SESSION 2	Chair: Jonathan Ledermann, UK
20'	Biology and staging of high grade tubo-epithelial cancers	Glenn McCluggage, UK
20'	Surgery for advanced ovarian cancer	Christina Fotopoulou, UK
30'	First-line chemotherapy treatment - Current results and challenges	Susana Banerjee, UK
20'	Intraperitoneal chemotherapy - Does it have a place in treatment?	Iain McNeish, UK
12:45-13:45	Lunch	
13:45-15:55 130'	SESSION 3	Chair: Mansoor Mirza, DK
3x10'	WORKSHOP 1: Primary or delayed surgery for ovarian cancer 3 x Participant clinical case discussion	Christina Fotopoulou, UK Christian Marth, AT
20'	Overview of treatment of recurrent ovarian cancer	Jonathan Ledermann, UK
30'	Anti-angiogenic treatments for recurrent ovarian cancer - When, which and for how long?	Nicoletta Colombo, IT
30'	PARP inhibitors - Current applications and future prospects	Jonathan Ledermann, UK
20'	Biology of drug resistance	Cristiana Sessa, CH
15:55-16:25	Coffee Break	
16:25-17:55 90'	SESSION 4	Chair: Nicoletta Colombo, IT
3x10'	WORKSHOP 2: Decision-making in recurrent ovarian cancer 3 x Participant clinical case discussion	Nicoletta Colombo, IT Mansoor Mirza, DK
20'	Patient reported outcomes and quality of life	Mansoor Mirza, DK
20'	Disease assessment and novel imaging	Andrés M. Poveda, ES
20'	A clinician's guide to cancer genomics	Cristiana Sessa, CH
19:00	Dinner	

Saturday, 22 April 2017

08:30-09:30 60'	SESSION 5	Chair: Iain McNeish, UK
20'	Surgery for recurrent disease and palliative surgery	Christina Fotopoulou, UK
20'	Novel treatment pathways - Horizon scanning	Cristiana Sessa, CH
20'	Management of ovarian cancer in the elderly	Susana Banerjee, UK
9:30-10:00	Coffee Break	
10:00-11:20 80'	SESSION 6	Chair: Isabelle Ray-Coquard, FR
2x10'	WORKSHOP 3: Clinical trial design and endpoints 2 x Participant clinical case discussion	Jonathan Ledermann, UK Mansoor Mirza, DK
20'	Clear cell cancer - Biology and therapy	Iain McNeish, UK
30'	Immunotherapy - Current evidence and future prospects	Christian Marth, AT
11:20-12:20 60'	SESSION 7	Chair: Cristiana Sessa, CH
20'	Rare epithelial and non-epithelial tumours - Treatment and networks for research	Isabelle Ray-Coquard, FR
20'	Review of 5 th Ovarian Cancer Consensus Conference, Tokyo 2015	Andrés M. Poveda, ES
20'	Germ cell tumours - Classification and management	Nicoletta Colombo, IT
12:20-12:35 15'	Conclusion and farewell	Jonathan Ledermann, UK
12:35-13:35	Lunch	

Note: Each 10 min slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion